KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Current Deferred Revenue (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Current Deferred Revenue data on record, last reported at $35.3 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 4.33% year-over-year to $35.3 million; the TTM value through Dec 2025 reached $35.3 million, up 4.33%, while the annual FY2025 figure was $35.3 million, 4.33% up from the prior year.
  • Current Deferred Revenue reached $35.3 million in Q4 2025 per IDXX's latest filing, down from $35.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $41.6 million in Q1 2021 and bottomed at $33.8 million in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $38.3 million, with a median of $38.0 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: increased 13.25% in 2021, then decreased 9.13% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $40.0 million in 2021, then fell by 5.24% to $37.9 million in 2022, then fell by 1.96% to $37.2 million in 2023, then fell by 9.13% to $33.8 million in 2024, then grew by 4.33% to $35.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $35.3 million in Q4 2025, $35.7 million in Q3 2025, and $36.3 million in Q2 2025.